Emergent BioSolutions Inc. (NYSE:EBS) Director Sells $204,050.00 in Stock

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares of the company's stock, valued at $589,413. This trade represents a 25.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Emergent BioSolutions Stock Up 11.8 %

Shares of Emergent BioSolutions stock traded up $0.66 during trading on Wednesday, hitting $6.19. 1,519,438 shares of the stock traded hands, compared to its average volume of 2,634,022. The stock has a market cap of $336.07 million, a P/E ratio of -1.51 and a beta of 1.80. The company has a fifty day moving average price of $9.17 and a two-hundred day moving average price of $8.89. Emergent BioSolutions Inc. has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. The firm had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the previous year, the company earned ($0.77) earnings per share. Equities research analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EBS has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, March 4th. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Remove Ads

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. acquired a new position in Emergent BioSolutions during the third quarter worth $1,547,000. Oak Hill Advisors LP acquired a new position in shares of Emergent BioSolutions during the 3rd quarter valued at about $9,296,000. Barclays PLC increased its holdings in shares of Emergent BioSolutions by 361.6% during the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock valued at $329,000 after acquiring an additional 30,792 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Emergent BioSolutions by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company's stock valued at $4,861,000 after acquiring an additional 25,776 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in Emergent BioSolutions by 41.7% in the 4th quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company's stock worth $2,928,000 after purchasing an additional 90,113 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.